Stifel on Blueprint Medicines (BPMC): 'We think fear around Ayvakit's growth offers an attractive entry point that may not last'
Tweet Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $155.00 price target on Blueprint Medicines (NASDAQ: BPMC)The analyst comments "Christina ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
